Fundamenta Therapeutics, Ltd.
- Country
- Ownership
- Private
- Established
- 1978-01-01
- Employees
- -
- Market Cap
- -
Safety and Efficacy of ThisCART19A Bridging Hematopoietic Stem Cell Transplantation in Patients With Refractory or Relapsed B-cell Acute Lymphoblastic Leukemia
Phase 1
Not yet recruiting
- Conditions
- Allogeneic, CAR-T, Protein Sequestration, Non-gene Edited
- Interventions
- First Posted Date
- 2022-10-12
- Last Posted Date
- 2022-10-12
- Lead Sponsor
- Fundamenta Therapeutics, Ltd.
- Target Recruit Count
- 19
- Registration Number
- NCT05576181
Safety and Efficacy of ThisCART7 in Patients With Refractory or Relapsed T Cell Malignancies
Phase 1
- Conditions
- T-cell Acute Lymphoblastic LymphomaT-Acute Lymphoblastic LeukemiaT-cell Non-Hodgkin Lymphoma
- Interventions
- Biological: ThisCART7 cells
- First Posted Date
- 2021-11-19
- Last Posted Date
- 2021-11-19
- Lead Sponsor
- Fundamenta Therapeutics, Ltd.
- Target Recruit Count
- 30
- Registration Number
- NCT05127135
- Locations
- 🇨🇳
Fundamenta Therapeutice Co.,Ltd, Suzhou, Jiangsu, China
🇨🇳The First Affiliated Hospital of USTC (Anhui Provincial Hospital), Hefei, Anhui, China
Safety and Clinical Activity of ThisCART22 in Patients With r/r Non-Hodgkin's B Cell Lymphoma
Phase 1
Recruiting
- Conditions
- B-cell Malignancy
- Interventions
- Biological: ThisCART22 cells
- First Posted Date
- 2021-11-04
- Last Posted Date
- 2021-11-11
- Lead Sponsor
- Fundamenta Therapeutics, Ltd.
- Target Recruit Count
- 20
- Registration Number
- NCT05106946
- Locations
- 🇨🇳
The Affiliated Hospital of Xuzhou Medical University, Xuzhou, Jiangsu, China
Safety and Clinical Activity of ThisCART19 in Patients With r/r Non-Hodgkin's B Cell Lymphoma
Phase 1
Recruiting
- Conditions
- B-cell Malignancy
- Interventions
- Biological: ThisCART19 cells
- First Posted Date
- 2021-11-04
- Last Posted Date
- 2021-11-04
- Lead Sponsor
- Fundamenta Therapeutics, Ltd.
- Target Recruit Count
- 20
- Registration Number
- NCT05106907
- Locations
- 🇨🇳
The Affiliated Hospital of Xuzhou Medical University, Xuzhou, Jiangsu, China
Safety and Efficacy of ThisCART22 in Patients With Refractory or Relapsed B Cell Malignancies
Phase 1
- Conditions
- B Cell Malignancy
- Interventions
- Biological: ThisCART22 cells injection
- First Posted Date
- 2020-10-23
- Last Posted Date
- 2020-12-01
- Lead Sponsor
- Fundamenta Therapeutics, Ltd.
- Target Recruit Count
- 20
- Registration Number
- NCT04601181
- Locations
- 🇨🇳
The First Affiliated Hospital of USTC (Anhui Provincial Hospital), Hefei, Anhui, China
Safety and Efficacy of ThisCART19 in Patients With Refractory or Relapsed B Cell Malignancies
Phase 1
- Conditions
- B Cell Malignancy
- Interventions
- Biological: ThisCART19 cells
- First Posted Date
- 2020-05-12
- Last Posted Date
- 2022-01-11
- Lead Sponsor
- Fundamenta Therapeutics, Ltd.
- Target Recruit Count
- 30
- Registration Number
- NCT04384393
- Locations
- 🇨🇳
Fundamenta Therapeutice Co.,Ltd, Suzhou, Jiangsu, China
🇨🇳The First Affiliated Hospital of USTC (Anhui Provincial Hospital), Hefei, Anhui, China
© Copyright 2025. All Rights Reserved by MedPath